2022 Pivotal Points, Currents, and Controversies in nr-axSpA: What You May Have Missed
Released On
January 4, 2023
Expires On
January 4, 2024
Media Type
Internet
Completion Time
45 minutes
Specialty
Pain Management, Rheumatology
Topic(s)
Arthritis, Biosimilars, Pain
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Integrity Continuing Education, Inc.
This activity is supported by an educational grant from AbbVie Inc.
Credit Available
- Physicians — maximum of 0.75 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity has been designed to meet the needs of rheumatologists, internal medicine physicians, and other clinicians who manage patients with nonradiographic axial spondyloarthritis (nr-axSpA), including rheumatology-specialist nurse practitioners and physician assistants.
Program Overview
Axial spondyloarthritis (axSpA) is now thought to be a disease continuum from early, nonradiographic disease (nr-axSpA), to more advanced disease that is easily detectable by radiograph (r-axSpA, better known as ankylosing spondyloarthritis [AS]). However, these delineations are not clear cut and not without controversy.
In 2022, the nuances of the axSpA disease spectrum began to take firmer definition as experts in this rheumatologic disorder offered greater clarity toward arriving at consensus on how to detect nr-axSpA and differentiate between it and r-axSpA/AS. Additionally, 3 biologics and 1 Janus kinase (JAK) inhibitor were approved by the FDA in 2022 specifically for the treatment of nr-axSpA.
Join axSpA expert Dr. Atul Deodhar to find out what rheumatologists and other healthcare professionals who care for patients with axSpA need to know about how to evaluate nr-axSpA and what to know about the new and emerging treatments that are designed specifically for nr-axSpA.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Review published data that define nr-axSpA within the axSpA disease continuum to facilitate more timely diagnoses
- Incorporate recently approved or emerging biologic and small-molecule treatments for appropriately selected patients with nr-axSpA, based on efficacy and safety data from clinical trials
Faculty
Atul Deodhar, MD
Professor of Medicine
Medical Director, Rheumatology Clinics
Division of Arthritis and Rheumatic Diseases
Oregon Health and Science University
Portland, Oregon
Physician Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:
- Atul Deodhar, MD
-
- Advisory Board: AbbVie, Eli Lilly, Janssen and UCB, Novartis
- Consultant: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen and UCB, MoonLake, Novartis
- Research grant: Bristol Myers Squibb, Celgene, Eli Lilly, Janseen and UCB, MoonLake, Novartis
- Speaker: Janssen and UCB
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of January 4, 2023 through January 4, 2024, participants must:
- Read the learning objectives
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.